Business Description
Invion Ltd
ISIN : AU000000IVX4
Total Employee Number:
4Compare
Compare
Traded in other countries / regions
IVX.Australia7C8.GermanyIVIXF.USA IPO Date
2011-12-23Description
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.22 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.14 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -14.1 | |||||
3-Year EPS without NRI Growth Rate | -45 | |||||
3-Year FCF Growth Rate | 33.1 | |||||
3-Year Book Growth Rate | -31.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.14 | |||||
Quick Ratio | 0.14 | |||||
Cash Ratio | 0.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.8 | |||||
Shareholder Yield % | -70.27 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -116.32 | |||||
ROA % | -100.25 | |||||
ROIC % | -95.74 | |||||
3-Year ROIIC % | 209.58 | |||||
ROC (Joel Greenblatt) % | -46843.55 | |||||
ROCE % | -107.23 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.6 | |||||
EV-to-EBIT | -0.51 | |||||
EV-to-EBITDA | -1.12 | |||||
EV-to-FCF | -1.88 | |||||
Price-to-GF-Value | 0.22 | |||||
Earnings Yield (Greenblatt) % | -196.08 | |||||
FCF Yield % | -58.9 |
Invion Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Invion Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.01:1 Stock Split | 2024-11-20 | 0.22 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:IVIXF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Invion Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers